Michel Sadelain, MD, PhD, on the Road to Synthetic Immunity: Novel CAR Designs

April 16, 2021 By The ASCO Post Staff

Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the challenges in developing CAR T-cell therapy, as well as the progress being made, such as creating hybrid CAR and T-cell receptors that should enable T cells to recognize much lower levels of antigens. The field, he says, is poised to take on a range of solid tumors to extend the successes in hematologic malignancies.

Related Content